Table 3.
Cross-resistance profiles. Cells (3 × 103·mL−1) were treated for 72 h with increasing concentrations of tested compounds. Cytotoxicity was assessed by MTT test. IC50 values were calculated by a four parameter logistic model (p < 0.05). RF = IC50 resistant/IC50 parental cell lines. S.D. = standard deviation.
| Compound | IC50 (µM) ± D.S. | ||
|---|---|---|---|
| 2008 | C13* | RF | |
| [HB(pz)3]Ag(PTA) (1) | 6.7 ± 3.2 | 7.4 ± 1.5 | 1.1 |
| [HB(pz)3]Ag(DAPTA) (2) | 8.9 ± 4.2 | 8.4 ± 1.3 | 0.9 |
| [HB(pz)3]Ag(PTA-SO2) (3) | 6.3 ± 1.1 | 5.6 ± 1.4 | 0.9 |
| [HB(pz)3]Ag(PCN) (4) | 7.8 ± 2.4 | 6.5 ± 1.8 | 0.9 |
| [HB(pz)3]Ag(PPh3) (5) | 2.02 ± 1.2 | 2.1 ± 1.5 | 1.0 |
| [Ag(PTA)4]BF4 (6) | 9.23 ± 2.0 | 10.9 ± 3.5 | 1.2 |
| [Ag(DAPTA)4]BF4 (7) | 10.3 ± 3.1 | 13.4 ± 2.4 | 1.3 |
| [Ag(PTA-SO2)4]BF4 (8) | 13.2 ± 2.5 | 16.3 ± 3.3 | 1.2 |
| [Ag(PCN)2]BF4 (9) | 3.1 ± 0.6 | 4.1 ± 1.1 | 1.3 |
| [Ag(PPh3)4]BF4 (10) | 4.2 ± 0.8 | 6.1 ± 1.3 | 1.4 |
| Cisplatin | 2.3 ± 1.1 | 21.5 ± 3.0 | 9.5 |